Ventilator-associated pneumonia (VAP) is the most common type of nosocomial infection in the intensive care unit. Clinical diagnosis of VAP still depends on the results of microbial culture identification of lower respiratory tract specimens of suspected patients, which takes about one to three days. At present, there is no way to quickly determine the infection status of patients, and the initial anti-infection regimen can only rely on the experience of doctors, which leads to the abuse of antibiotics and the failure of initial treatment.
A research team led by Prof. Huang Ying from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has been conducting research aiming at a new non-invasive screening method for VAP. With a self-developed breath tester proton transfer reaction-mass spectrometry, they detected exhaled volatile organic compounds (VOCs) from patients infected with VAP.
Results were published in Talanta on Nov. 7.
In this study, the researchers proposed a mode of breath sampling for patients with endotracheal intubation/incision—deep airway breath sampling method.
Combined with the self-developed respiratory tester, breathing sampling and detection of patients with endotracheal intubation/incision only takes a few minutes. Characteristic ions that differentiate VAP were statistically detected in breath tests in infected and uninfected patients.
In addition, the main pathogens of infected patients were cultured in vitro to study the relationship between the iconic VOCs in the breath of VAP patients and the VOCs released by common pathogens.
The sensitivity and specificity were 71.4% and 84.4%, respectively. The results showed that exhaled acetaldehyde could be used to screen for VAP.
Source: Read Full Article